Patents by Inventor Dietmar Reusch

Dietmar Reusch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200325245
    Abstract: The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Sebastian Malik, Dietmar Reusch, Alfred Schn├╝riger, Max L. Tejada, Marco Thomann
  • Publication number: 20170253661
    Abstract: The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 7, 2017
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Sebastian Malik, Dietmar Reusch, Alfred Schn├╝riger, Max L Tejada, Marco Thomann
  • Patent number: 9365881
    Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: June 14, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martina Hueller, Dietmar Reusch
  • Publication number: 20140234899
    Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.
    Type: Application
    Filed: October 2, 2012
    Publication date: August 21, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Martina Hueller, Dietmar Reusch
  • Publication number: 20140193404
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: March 3, 2014
    Publication date: July 10, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Patent number: 8703919
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: April 22, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Patent number: 8524470
    Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (?1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: September 3, 2013
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Markus Haberger, Christine Jung, Dietmar Reusch
  • Publication number: 20120172255
    Abstract: Herein is reported a method for the determination of the glycosylation of an immunoglobulin with electrospray mass spectrometry but without the need for a chromatographic purification step after the digestion of the immunoglobulin and prior to the mass spectrometric analysis.
    Type: Application
    Filed: September 3, 2010
    Publication date: July 5, 2012
    Applicant: HOFFMANN-LA ROCHE, INC,
    Inventors: Markus Haberger, Dietmar Reusch, Maurice Selman, Manfred Wuhrer
  • Publication number: 20120129216
    Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (?1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.
    Type: Application
    Filed: July 28, 2010
    Publication date: May 24, 2012
    Inventors: Markus Haberger, Christine Jung, Dietmar Reusch
  • Publication number: 20120128664
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 24, 2012
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Publication number: 20110117601
    Abstract: The present invention provides a method for the production of a glycosylated heterologous polypeptide comprising the steps of obtaining a sample from a crude fermentation broth, incubation of the sample with magnetic affinity beads, releasing glycans from the immobilized glycosylated polypeptides, measuring a glycosylation profile, comparing the glycosylation profile with a desired glycosylation profile of the recombinant glycosylated polypeptide, modifying the culture conditions in accordance to the glycosylation profile obtained, and repeating the process in order to obtain a glycosylated heterologous polypeptide with the desired glycosylation profile. With a similar method diagnostic markers can be identified and quantified.
    Type: Application
    Filed: August 20, 2008
    Publication date: May 19, 2011
    Inventors: Markus Haberger, Dietmar Reusch
  • Publication number: 20100322927
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: September 1, 2010
    Publication date: December 23, 2010
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Patent number: 7846724
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: December 7, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Publication number: 20080014203
    Abstract: An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 98%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha-1,3-galactose is 1% or less has improved properties in antitumor therapy.
    Type: Application
    Filed: April 5, 2007
    Publication date: January 17, 2008
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Publication number: 20070248600
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 25, 2007
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher